Anti-CD2 monoclonal antibody OX34

Drug Profile

Anti-CD2 monoclonal antibody OX34

Alternative Names: CD2 antibody OX34; CD2 monoclonal antibody OX34; OX34; OX34 antibody

Latest Information Update: 23 Aug 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator DKFZ; National Cancer Institute (USA)
  • Developer National Cancer Institute (USA)
  • Class Monoclonal antibodies
  • Mechanism of Action CD2 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Transplant rejection

Most Recent Events

  • 10 Aug 1998 A study has been added to the Transplant rejection pharmacodynamics section
  • 23 Dec 1996 A study has been added to the Transplant Rejection pharmacodynamics section
  • 02 Nov 1994 Preclinical development for Transplant rejection in Germany (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top